Cited by 151Neurogenesis and neuroplasticity mechanismsNeurofibromatosis and Schwannoma CasesGenetics and Neurodevelopmental Disorders

ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities

Open access
Wang, Yuan, Kim, Edward, Wang, Xiaojing, Novitch, Bennett G., Yoshikawa, Kazuaki, Chang, Long-Sheng, Zhu, Yuan·2012·Cell

Abstract

Germline mutations in the RAS/ERK signaling pathway underlie several related developmental disorders collectively termed neuro-cardio-facial-cutaneous (NCFC) syndromes. NCFC patients manifest varying degrees of cognitive impairment, but the developmental basis of their brain abnormalities remains largely unknown. Neurofibromatosis type 1 (NF1), an NCFC syndrome, is caused by loss-of-function heterozygous mutations in the NF1 gene, which encodes neurofibromin, a RAS GTPase-activating protein. Here, we show that biallelic Nf1 inactivation promotes Erk-dependent, ectopic Olig2 expression specifically in transit-amplifying progenitors, leading to increased gliogenesis at the expense of neurogenesis in neonatal and adult subventricular zone (SVZ). Nf1-deficient brains exhibit enlarged corpus callosum, a structural defect linked to severe learning deficits in NF1 patients. Strikingly, these NF1-associated developmental defects are rescued by transient treatment with an MEK/ERK inhibitor during neonatal stages. This study reveals a critical role for Nf1 in maintaining postnatal SVZ-derived neurogenesis and identifies a potential therapeutic window for treating NF1-associated brain abnormalities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2012.06.034

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Activity of β-catenin enhances premature differentiation of neurons, while activity of RAS/ERK reduces neurogenesis of IPCs and increases astrogenesis.

    “Activity of β-catenin (downstream of PI3K/AKT and WNT, Fig. 6) enhances premature differentiation of neurons [88], while activity of RAS/ERK reduces neurogenesis of IPCs and increases astrogenesis [90].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wang, Y., Kim, E., Wang, X., Novitch, B. G., Yoshikawa, K., Chang, L.-S., & Zhu, Y.
Affiliations
  • University of Michigan (US)
  • University of California, Los Angeles (US)
  • Institute for Protein Research, The University of Osaka (JP)
  • Nationwide Children's Hospital (US)
Corresponding author
Zhu, Yuan
Venue
Cell
Publisher
Elsevier BV
Published
2012-08
Volume
150
Issue
4
Pages
816-830
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2087705653
Cited by
151
References
52
Citations by year
2026: 3 · 2025: 9 · 2024: 13 · 2023: 8 · 2022: 8 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 10 · 2012: 4
FWCI
4.30
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1R01 NS053900)
  • U.S. Department of Defense (W81XWH-11-1-0251)
Topics
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Health Sciences › Medicine › Neurology › Neurofibromatosis and Schwannoma Cases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
neurofibromatosis type 1, Ras/ERK signaling, MEK/ERK inhibitor, neural progenitor cells, subventricular zone, gliogenesis, neurogenesis, Olig2, learning deficits, neurofibromin
MeSH terms
Oligodendrocyte Transcription Factor 2, Animals, Brain, Corpus Callosum, Humans, Nerve Tissue Proteins, Neurofibromatosis 1, Neuroglia, Mice, Knockout, MAP Kinase Signaling System, Neurofibromin 1, Mice, Basic Helix-Loop-Helix Proteins, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review